Skip to main content
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. — Investor Relations & Filings

Ticker · KAPA ISIN · US48301N1046 US Professional, scientific and technical activities
Filings indexed 110 across all filing types
Latest filing 2025-03-28 Regulatory Filings
Country US United States of America
Listing US KAPA

About Kairos Pharma, LTD.

https://kairospharma.com

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. The company's primary focus is on overcoming key hurdles in cancer treatment, specifically drug resistance and immune suppression. Its lead product candidate, ENV105, is an antibody that targets the CD105 protein to reverse resistance to existing cancer drugs. ENV105 is in mid-stage clinical trials for prostate cancer and early-stage trials for lung cancer. In addition, Kairos is developing a pipeline of immunotherapies designed to reverse cancer-induced immune suppression. This includes KROS101, a small molecule to enhance T cell activity, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma, for which an Investigational New Drug (IND) application has been cleared.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-03-28 English
Regulatory Filings 2025
Regulatory Filings
2025-03-20 English
Regulatory Filings 2025
Regulatory Filings
2025-02-26 English
Director's Dealing 2025
Director's Dealing
2025-02-25 English
Director's Dealing 2025
Director's Dealing
2025-02-25 English
Regulatory Filings 2025
Regulatory Filings
2025-02-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.